DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
Provided By PR Newswire
Last update: Sep 4, 2024
CUPERTINO, Calif., Sept. 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the H.C. Wainwright 26th Annual Global Investment Conference to take place September 9-11, 2024 in New York City.
Read more at prnewswire.com
